PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s CEO Ahmed Hamdy, M.D. and the Management Team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference 2023, to be held in New York, NY, September 26-28, 2023.
Conference Presentation Details
Panel Date/Time: | Wednesday, September 27, 2023 at 9:10 a.m. ET |
Speaker: | CEO Ahmed Hamdy, M.D. |
Investor Access: | https://wsw.com/webcast/cantor19/vinc/2095632 |
1X1 meetings | The Vincerx Management Team will be available for 1X1 meetings during the conference. Those interested in requesting a meeting should contact their Cantor Fitzgerald sales representative. |
A copy of the Company corporate presentation is available here and a recording of the panel presentation can be accessed through the “ Investor Calendar ” section of the Vincerx website where it will be archived for 90 days.
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (Vincerx) is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. The company’s diverse pipeline consists of the next-generation antibody conjugate, VIP943, in Phase 1; small molecule drug-conjugate, VIP236, in Phase 1; preclinical antibody drug conjugate, VIP924; CDK9 inhibitor, enitociclib, currently in an NIH-sponsored Phase 1; and its next-generation modular bioconjugation platform.
Vincerx is based in Palo Alto, California, and has a research facility in Monheim, Germany. For more information, please visit www.vincerx.com .
Contacts
Joyce Lonergan
LifeSci Advisors, LLC
781-528-5276
jlonergan@lifesciadvisors.com